Niagen Bioscience (NASDAQ:NAGE) Given New $7.00 Price Target at Canaccord Genuity Group

Niagen Bioscience (NASDAQ:NAGE) had its target price cut by Canaccord Genuity Group from $9.00 to $7.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages have also commented on NAGE. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, October 15th. Roth Capital reiterated a “buy” rating on shares of Niagen Bioscience in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $8.50.

Niagen Bioscience Stock Performance

Shares of NAGE stock traded down $0.04 during trading hours on Friday, hitting $2.07. 597,674 shares of the company were exchanged, compared to its average volume of 480,554. The firm has a market cap of $164.85 million, a P/E ratio of 17.25 and a beta of 2.12. Niagen Bioscience has a fifty-two week low of $2.04 and a fifty-two week high of $7.28. The company has a 50 day simple moving average of $2.76 and a two-hundred day simple moving average of $3.83.

Niagen Bioscience (NASDAQ:NAGE) last released its earnings results on Wednesday, November 4th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01). The company had revenue of $27.19 million for the quarter. Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%. As a group, sell-side analysts expect that Niagen Bioscience will post 0.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Niagen Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. SteelPeak Wealth LLC acquired a new position in Niagen Bioscience during the 1st quarter valued at about $14,875,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Niagen Bioscience by 47.1% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company’s stock worth $10,489,000 after purchasing an additional 761,685 shares during the last quarter. Tieton Capital Management LLC purchased a new stake in shares of Niagen Bioscience in the second quarter worth approximately $6,407,000. Sei Investments Co. lifted its holdings in shares of Niagen Bioscience by 155.6% in the first quarter. Sei Investments Co. now owns 971,574 shares of the company’s stock valued at $4,285,000 after purchasing an additional 591,495 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Niagen Bioscience by 45.4% in the first quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company’s stock valued at $5,860,000 after purchasing an additional 414,725 shares in the last quarter. Institutional investors and hedge funds own 15.41% of the company’s stock.

Key Niagen Bioscience News

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Management highlighted positive cash flow on its Q3 earnings call, while the company outlined plans for a 5,000-participant, three-year Mass General Brigham trial and is targeting early-2027 commercialization of NR malate. These developments could support longer-term growth, though execution and commercialization remain ahead. Q3 2026 earnings call highlights Trial and commercialization plans
• Neutral Sentiment: Canaccord Genuity lowered its price target to $7 from $9 but maintained a Buy rating. The reduced target is a setback, while the continued Buy rating signals the analyst still sees substantial potential from the referenced $2.07 share price. Canaccord price-target update
• Negative Sentiment: HC Wainwright cut its Q3 and Q4 2026 estimates to losses of $0.02 per share each, and reduced its full-year 2026 and 2027 EPS forecasts to $0.05 from $0.14. It also lowered estimates across 2027 quarters, indicating weaker expected profitability. Analyst estimate updates
• Negative Sentiment: Niagen reported a Q3 loss of $0.01 per share, in line with expectations but down from earnings of $0.05 a year earlier; revenue also missed estimates, adding to near-term concerns. Q3 results

About Niagen Bioscience

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.